In a notable shift in approach to mental health within the US military, active-duty soldiers suffering from Post-Traumatic Stress Disorder (PTSD) are set to receive MDMA-assisted therapy. This initiative is part of two new studies funded by the Department of Defense (DoD), with sessions anticipated to begin next year.
The trials will involve 186 service personnel diagnosed with PTSD, who will undergo multiple sessions of MDMA-assisted therapy. The hope is that these sessions could help soldiers process their trauma, potentially enabling them to continue their service and improve their overall well-being.
This move represents a significant departure from traditional military mental health treatments and a new frontier in the US 'war on drugs', where psychedelic substances are now being explored for their therapeutic potential. The research aims to evaluate the efficacy and safety of MDMA when used in a controlled, therapeutic setting to address the severe psychological impact of combat and service-related trauma.
The studies reflect a growing interest in the therapeutic applications of previously illicit substances, particularly for conditions like PTSD that can be resistant to conventional treatments. If successful, these trials could pave the way for a new doctrine in how the US military supports its personnel struggling with the lasting effects of their service.